The present disclosure relates to a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof, and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
本公开涉及a) N-((R)-2,3-二羟基丙氧基)-3,4-二
氟-2-(2-
氟-4-
碘苯基
氨基)-苯甲酰的晶型形式;b) 包含一种或多种N-((R)-2,3-二羟基丙氧基)-3,4-二
氟-2-(2-
氟-4-
碘苯基
氨基)-苯甲酰的晶型形式的药物组合物,以及可选地,一种或多种药用可接受的载体;c) 通过向需要的受试者施用一种或多种N-((R)-2,3-二羟基丙氧基)-3,4-二
氟-2-(2-
氟-4-
碘苯基
氨基)-苯甲酰的晶型形式来治疗肿瘤、癌症或Ras病的方法,并且生产基本纯净的N-((R)-2,3-二羟基丙氧基)-3,4-二
氟-2-(2-
氟-4-
碘苯基
氨基)-苯甲酰的IV型的方法。